Sustained response to pembrolizumab without prior chemotherapy in high-grade serous ovarian carcinoma with CSMD3 mutation

• Metastatic CSMD3 mutated HGSOC showed objective and sustained response to pembrolizumab. • The tumor was massively infiltrated by CD8(+) T cells while PD-L1 TPS was at 10%. • CSMD3 mutated HGSOC showed up-regulation of CCL5 and CXCL9.

Detalles Bibliográficos
Autores principales: Terzic, Julie, Seipel, Amanda, Dubuisson, Jean, Tille, Jean-Christophe, Tsantoulis, Petros, Addeo, Alfredo, Labidi-Galy, S.Intidhar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7322246/
https://www.ncbi.nlm.nih.gov/pubmed/32613071
http://dx.doi.org/10.1016/j.gore.2020.100600
Descripción
Sumario:• Metastatic CSMD3 mutated HGSOC showed objective and sustained response to pembrolizumab. • The tumor was massively infiltrated by CD8(+) T cells while PD-L1 TPS was at 10%. • CSMD3 mutated HGSOC showed up-regulation of CCL5 and CXCL9.

Ejemplares similares